| Drug General Information |
| Drug ID |
D03AJX
|
| Former ID |
DNC001157
|
| Drug Name |
PS-341
|
| Drug Type |
Small molecular drug
|
| Indication |
Mantle cell lymphoma [ICD9: 200.4, 202.8, 203.0, 208.9; ICD10:C81-C86, C85.7, C90.0, C91-C95]
|
Approved |
[1],
[2]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H25BN4O4
|
| Canonical SMILES |
B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
|
| InChI |
1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m1/s1
|
| InChIKey |
GXJABQQUPOEUTA-NVXWUHKLSA-N
|
| CAS Number |
CAS 179324-69-7
|
| PubChem Compound ID |
|
| PubChem Substance ID |
44424531, 49895087, 50113272, 50726121, 57335697, 92719226, 103565488, 104411215, 124893550, 126575146, 126620978, 126658246, 126667091, 126727554, 134338534, 135051251, 135727461, 137001833, 140705866, 141088999, 160963536, 196109699, 223662143, 226395803, 243055978, 251971017, 252671873
|
| ChEBI ID |
ChEBI:52717
|
| SuperDrug ATC ID |
L01XX32
|
| SuperDrug CAS ID |
cas=179324697
|
| Target and Pathway |
| Target(s) |
Nuclear factor NF-kappa-B |
Target Info |
Inhibitor |
[3]
|
|---|
| 20S proteasome |
Target Info |
Inhibitor |
[4]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Legionellosis
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
PANTHER Pathway
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
T cell activation
|
|
Toll receptor signaling pathway
|
|
Pathway Interaction Database
|
IL12-mediated signaling events
|
|
Alternative NF-kappaB pathway
|
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
|
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
|
Reactome
|
RIP-mediated NFkB activation via ZBP1
|
|
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
Interleukin-1 processing
|
|
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
|
|
IkBA variant leads to EDA-ID
|
|
Dectin-1 mediated noncanonical NF-kB signaling
|
|
NIK-->noncanonical NF-kB signaling
|
|
TRAF6 mediated NF-kB activation
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
SIDS Susceptibility Pathways
|
|
Nuclear Receptors Meta-Pathway
|
|
Cytosolic sensors of pathogen-associated DNA
|
|
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
|
EBV LMP1 signaling
|
|
TNF alpha Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
Neural Crest Differentiation
|
|
TWEAK Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
|
|
Interleukin-1 processing
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007364) |
|---|
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
|---|
| REF 3 | Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 1;99(11):4079-86. |
|---|
| REF 4 | Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. |
|---|
